🔗 Share this article

While America proceeds with unprecedented adjustments to its vaccination recommendations, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by expressing skepticism about coronavirus vaccinations throughout the pandemic and has focused upon potential deaths following COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Program

Health officials had intended to announce major revisions to the childhood immunization program recently, bringing the US with the Danish immunization schedule, it is understood – a major change that would place the US at odds with much of the world with little proof for benefit. The announcement has been postponed until the next year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to speak at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to run the center this year.

A Shift at the Agency

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad consolidate power at the agency – and it points to a renewed priority upon rolling back long-standing immunizations at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric shot schedules in the US so as to align more similar to Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

So far public appearances, she has continued to focus on immunizations – typically the purview of Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Expertise

Høeg has little discernible track record in medication creation, regulation or administrative roles, which has been customary for previous directors of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and CBER since spring.

“She appears not to have the requisite experience” for running the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Previous heads of CBER would “be deeply familiar with legal statutes and the research of medication creation”, said Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who led CBER have had.”

CDER has an vast range of responsibilities at the FDA, the former commissioner stated.

“The public just focuses on the innovative therapies, but the generic program authorizes numerous off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and so forth, and all of those have to be managed,” Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to bite you.”

There is also, a significant management component to the job, which manages more than 5,000 employees. “It’s a huge management job, if you perform it correctly,” Woodcock concluded.

Agency Reaction and Disputed Programs

When asked about inquiries about Høeg’s qualifications and whether this selection represents increased cooperation among agency officials on immunizations, a spokesperson said that the “questions are based on incorrect presumptions”.

“This background matches the duties of her position,” the spokesperson explained, pointing to the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg inherits the agency head's recently launched priority voucher program, a contentious rapid drug-approval program that allegedly concerned her former heads. “How are these medications being chosen for this expedited pathway? Who takes the choices?” Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

Overall, he said, “the FDA appears to be shifting towards more relaxed regulations of pharmaceuticals, aside from shots.”

Documented Track Record on Immunizations

With vaccines, Høeg has a more documented, if problematic, track record, some experts have noted. She published a research paper using unverified public submissions to estimate the incidence of heart inflammation after COVID-19 vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccines are more dangerous than they are.

Included in her “desired changes” for the new government included altering rules for new vaccines and ending “optional” vaccines, she remarked after the election on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of excluding young men from obtaining COVID-19 vaccines.

“She is an complete ideologue who commences with her conclusions and reverse-engineers to fit the science in a very disingenuous, dishonest way,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|